

January 01, 2026

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Intimation of Press Release – Acquisition of ANDAs

Attaching herewith a Press Release regarding acquisition of ten approved Abbreviated New Drug Applications (ANDAs) for Injectable and Ophthalmic products from a leading Multinational Generic product manufacturing company.

Kindly take the same on your records.

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G
General Counsel & Company Secretary
Membership No A23989

CAPLIN ACQUIRES 10 APPROVED ANDAs INJECTION AND OPHTHALMIC PRODUCTS

Chennai, January 1st, 2026: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), through its subsidiary companies of Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL) has acquired 10 approved ANDAs for Injectable and Ophthalmic products from a leading Multinational Generic product manufacturing company. These products' addressable market was \$ 473.2 million for the 12-month period ending August 2025.

Commenting on the acquisition, Mr. C.C. Paarhipan, Chairman said, "The U.S. market remains a key growth engine for the Company, and this acquisition meaningfully accelerates our strategy by expanding and strengthening our portfolio in the region. The acquired portfolio also includes select oncology injectables, which will be transferred to and commercialized from our new dedicated oncology facility in Kakkalur. In addition, we intend to progressively extend these products to key non-U.S. markets, including Mexico, Canada, the European Union, and Brazil."

About Caplin:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. Caplin Point is one of the few companies to show consistent high-quality growth in cash flows, Profitability and Revenues over the last 15 years. Caplin Point has appeared on Forbes "Asia's 200 Best Under a Billion" list for an unprecedented 7th time in the last 10 years, and was awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

Caplin Steriles Limited (CSL), a Subsidiary of Caplin Point Laboratories Limited, is a fast growing sterile product manufacturing company that is approved by several regulatory agencies such as US FDA, EU-GMP, ANVISA and INVIMA. CSL has developed and filed 53 ANDAs in USA on its own and with partners, with 49 approvals (including acquired ANDA's) so far. CSL is also working on a portfolio of 55+ simple and complex Injectable and Ophthalmic products that it intends to file over the next 4 years. CSL also has multiple products filed with several approvals in non-US markets such as Australia, Canada, Mexico, Chile, UAE, Hong Kong, Malaysia, South Africa, Saudi Arabia etc. Caplin One Labs Limited (COL), a Subsidiary of Caplin Point Laboratories Limited, is into the second year of its operations at its oncology unit in Kakkalur, with various ongoing projects in different stages of completion for generic and specialty products for both regulated and other markets. COL has acquired 5 out of the 10 ANDAs for Injectable and Ophthalmic products covered under the current acquisition.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

| | |
|---|---|
| Investor Relations at Caplin Mr G Venkatram (General Counsel & Company Secretary) Tel: +91 44 24968000 investor@caplinpoint.net Churchgate Partners Anvita Raghuram / Rajiv Pandya +91 22 6169 5988 caplinpoint@churchgatepartners.com | Registered Office Caplin Point Laboratories Limited 3 rd Floor, Ashvich Tower, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096, Tamil Nadu, INDIA. Tel: +91 44 2496 8000 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 Website: www.caplinpoint.net |
|---|---|